Back to news
Pharmathen acquires CBL Patras
08-11-2023
We have acted as legal advisors of CBL Patras, as well as its shareholders, in connection with the acquisition of the company by Pharmathen, a leading European complex drug delivery and formulation developer.
Founded in 1990 by Professor Dr. Kleomenis Barlos, CBL Patras is one of the key peptide material suppliers in Europe, offering peptide starting materials and intermediates, as well as industrial and commercial-scale manufacturing of proprietary and generic GMP peptides.
This transaction is expected to unlock substantial commercial and R&D pipeline synergies and enhance the international reputation of the two parties, as well as, promote the Greek pharmaceutical sector globally.